Bacterial Infections News

Bacterial Infections	Welcome, Profile Billing Logout

«1 2...49 50 51 52 535455 56 57 58 59...65 66 »

||||||||||  Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial completion:  Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations (clinicaltrials.gov) -  Feb 10, 2013
P3, N=123, Completed,  Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed

||||||||||  ceftaroline fosamil / Generic mfg.
Trial withdrawal:  Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia (clinicaltrials.gov) -  Feb 6, 2013
P4, N=0, Withdrawn,  Sponsor: Cerexa, Inc.
Active, not recruiting --> Completed Recruiting --> Withdrawn

||||||||||  tigecycline / Generic mfg.
Trial initiation date:  Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens. (clinicaltrials.gov) -  Feb 6, 2013
P3, N=26, Completed,  Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting --> Withdrawn Initiation date: Sep 2003 --> Jan 2004

||||||||||  levofloxacin / Generic mfg., tigecycline / Generic mfg.
Trial initiation date:  Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia (clinicaltrials.gov) -  Feb 6, 2013
P3, N=434, Completed,  Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Initiation date: Sep 2003 --> Jan 2004 Initiation date: Sep 2003 --> Jan 2004

||||||||||  ceftaroline fosamil / Generic mfg.
Enrollment change:  Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia (clinicaltrials.gov) -  Feb 6, 2013
P4, N=0, Withdrawn,  Sponsor: Cerexa, Inc.
Initiation date: Sep 2003 --> Jan 2004 N=50 --> 0

||||||||||  vancomycin / Generic mfg.
New P4 trial:  Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients (clinicaltrials.gov) -  Feb 5, 2013
P4, N=120, Recruiting,  Sponsor: Massachusetts General Hospital

||||||||||  SQ-109 / Sequella
New P2 trial:  Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design (clinicaltrials.gov) -  Feb 5, 2013
P2, N=365, Active, not recruiting,  Sponsor: Michael Hoelscher

|||||||||| Enrollment change: The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) (clinicaltrials.gov) - Feb 4, 2013
P=N/A, N=65, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=50 --> 0 N=130 --> 65

||||||||||  azithromycin / Generic mfg.
New P4 trial:  RESCUE-L: Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) -  Feb 4, 2013
P4, N=20, Enrolling by invitation,  Sponsor: Pfizer

|||||||||| Enrollment open: Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid (clinicaltrials.gov) - Feb 4, 2013
P2, N=83, Enrolling by invitation, Sponsor: California Department of Public Health
N=130 --> 65 Not yet recruiting --> Enrolling by invitation

||||||||||  rifampicin / Generic mfg.
Enrollment closed:  Study of Daily Rifapentine for Pulmonary Tuberculosis (clinicaltrials.gov) -  Feb 4, 2013
P2, N=153, Active, not recruiting,  Sponsor: Johns Hopkins University
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting

||||||||||  Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi
Trial completion:  Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine (clinicaltrials.gov) -  Feb 4, 2013
P4, N=12020, Completed,  Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Trial initiation date: Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms (clinicaltrials.gov) - Feb 1, 2013
P=N/A, N=100, Recruiting, Sponsor: American University of Beirut Medical Center
Active, not recruiting --> Completed Initiation date: Mar 2011 --> Jul 2012

|||||||||| Enrollment open: Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms (clinicaltrials.gov) - Feb 1, 2013
P=N/A, N=100, Recruiting, Sponsor: American University of Beirut Medical Center
Initiation date: Mar 2011 --> Jul 2012 Not yet recruiting --> Recruiting

||||||||||  clarithromycin / Generic mfg., omeprazole / Generic mfg.
Trial completion:  Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients (clinicaltrials.gov) -  Feb 1, 2013
P=N/A, N=70, Completed,  Sponsor: Zagazig University
Not yet recruiting --> Recruiting Recruiting --> Completed

||||||||||  ceftaroline fosamil / Generic mfg.
Trial completion, Gram positive, Gram negative:  CERBERUS: Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia (clinicaltrials.gov) -  Jan 31, 2013
P=N/A, N=3000, Completed,  Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Completed

||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Nimenrix (MenACWY-TT) / Pfizer
New P1/2 trial:  Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines (clinicaltrials.gov) -  Jan 30, 2013
P1/2, N=16, Recruiting,  Sponsor: Leiden University Medical Center

|||||||||| Enrollment open: MVA(TB)029: Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination (clinicaltrials.gov) - Jan 29, 2013
P2, N=340, Recruiting, Sponsor: Mark Hatherill
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Trial completion:  TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) -  Jan 29, 2013
P3, N=666, Completed,  Sponsor: Trius Therapeutics, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed

|||||||||| New P2/3 trial, Combination therapy: TESEC-07: Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses (clinicaltrials.gov) - Jan 28, 2013
P2/3, N=450, Recruiting, Sponsor: Statens Serum Institut

|||||||||| Enrollment closed: Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test (clinicaltrials.gov) - Jan 28, 2013
P=N/A, N=2900, Active, not recruiting, Sponsor: Program for Appropriate Technology in Health
Recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Trial completion: Preliminary Evaluation of a Point-Of-Care Liver Function Test (clinicaltrials.gov) - Jan 28, 2013
P=N/A, N=700, Completed, Sponsor: Program for Appropriate Technology in Health
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Onbrez (indacaterol) / Novartis
New P3 trial:  INFINITY: Indacaterol EfectIveness In COPD Patients With Tuberculosis History (clinicaltrials.gov) -  Jan 27, 2013
P3, N=132, Recruiting,  Sponsor: Novartis Pharmaceuticals

|||||||||| Enrollment closed: MALTA: Can we Reduce the Number of Vaccine Injections for Children? (clinicaltrials.gov) - Jan 27, 2013
P4, N=498, Active, not recruiting, Sponsor: University of Oxford
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Nimenrix (MenACWY-TT) / Pfizer
New P3 trial:  Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (clinicaltrials.gov) -  Jan 24, 2013
P3, N=260, Recruiting,  Sponsor: GlaxoSmithKline

||||||||||  oral live-attenuated Shigella sonnei vaccine (WRSs2) / National Institute of Allergy and Infectious Diseases
Trial initiation date:  Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 (clinicaltrials.gov) -  Jan 23, 2013
P1, N=90, Recruiting,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Initiation date: Aug 2012 --> Jan 2013

|||||||||| Enrollment open: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Jan 21, 2013
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Initiation date: Aug 2012 --> Jan 2013 Not yet recruiting --> Recruiting

||||||||||  Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
Trial completion:  Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects (clinicaltrials.gov) -  Jan 21, 2013
P3, N=200, Completed,  Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Completed

||||||||||  biapenem / Generic mfg.
New P1 trial:  Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination (clinicaltrials.gov) -  Jan 17, 2013
P1, N=30, Completed,  Sponsor: Rempex Pharmaceuticals

||||||||||  NuThrax (AV7909) / Emergent Biosolutions
New P2 trial, P2 data:  A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels (clinicaltrials.gov) -  Jan 16, 2013
P2, N=168, Active, not recruiting,  Sponsor: Emergent BioSolutions

|||||||||| Enrollment closed: Early-Onset Sepsis Surveillance Study (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=615, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed Completed --> Active, not recruiting

||||||||||  Lamprene (clofazimine) / Novartis
Enrollment closed:  U-MDT: Uniform Multidrug Therapy Regimen for Leprosy Patients (clinicaltrials.gov) -  Jan 15, 2013
P4, N=2122, Active, not recruiting,  Sponsor: University of Brasilia
Completed --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| New P4 trial: Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection (clinicaltrials.gov) - Jan 14, 2013
P4, N=306, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.

|||||||||| Enrollment open: Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=400, Enrolling by invitation, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation

|||||||||| Biomarker, Enrollment change: Pharmacogenetics of Vitamin D Supplementation in Tuberculosis (clinicaltrials.gov) - Jan 13, 2013
P3, N=62, Completed, Sponsor: University of Birmingham
Not yet recruiting --> Enrolling by invitation N=80 --> 62

||||||||||  Trumenba (meningococcal B vaccine) / Pfizer
New P2 trial:  B1971042: Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (clinicaltrials.gov) -  Jan 13, 2013
P2, N=13, Completed,  Sponsor: Pfizer

|||||||||| Enrollment open: Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection (clinicaltrials.gov) - Jan 13, 2013
P4, N=306, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
N=80 --> 62 Not yet recruiting --> Recruiting

|||||||||| Biomarker, Trial completion: Pharmacogenetics of Vitamin D Supplementation in Tuberculosis (clinicaltrials.gov) - Jan 13, 2013
P3, N=62, Completed, Sponsor: University of Birmingham
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

||||||||||  azithromycin / Generic mfg.
New P4 trial:  A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial (clinicaltrials.gov) -  Jan 10, 2013
P4, N=52, Recruiting,  Sponsor: Johns Hopkins University

||||||||||  Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
New P3 trial:  Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age (clinicaltrials.gov) -  Jan 10, 2013
P3, N=692, Completed,  Sponsor: GlaxoSmithKline

||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P1 trial:  Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults (clinicaltrials.gov) -  Jan 10, 2013
P1, N=150, Completed,  Sponsor: GlaxoSmithKline

|||||||||| Trial completion: Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis (clinicaltrials.gov) - Jan 10, 2013
P1, N=60, Completed, Sponsor: JN-International Medical Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  SQ-109 / Sequella
Trial completion:  SQ109EBA: Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB (clinicaltrials.gov) -  Jan 10, 2013
P2a, N=90, Completed,  Sponsor: Michael Hoelscher
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial initiation date: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older (clinicaltrials.gov) - Jan 7, 2013
P=N/A, N=3000, Suspended, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Initiation date: Dec 2012 --> Mar 2013

||||||||||  doripenem / Generic mfg.
New P4 trial:  A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections (clinicaltrials.gov) -  Jan 6, 2013
P4, N=170, Completed,  Sponsor: Janssen Pharmaceutica

|||||||||| New P1/2 trial: GoldenCareTM for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Jan 6, 2013
P1/2, N=8, Terminated, Sponsor: CDA Research Group, Inc.

|||||||||| Enrollment open, Gram negative: Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia (clinicaltrials.gov) - Jan 5, 2013
P=N/A, N=400, Recruiting, Sponsor: Rabin Medical Center
Initiation date: Dec 2012 --> Mar 2013 Not yet recruiting --> Recruiting

||||||||||  levofloxacin / Generic mfg.
New P3 trial:  FLISH-ILT: "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". (clinicaltrials.gov) -  Jan 2, 2013
P3, N=870, Recruiting,  Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

||||||||||  Cubicin (daptomycin) / Merck (MSD)
Trial withdrawal:  Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation (clinicaltrials.gov) -  Dec 27, 2012
P=N/A, N=0, Withdrawn,  Sponsor: Federico II University
Not yet recruiting --> Recruiting Recruiting --> Withdrawn

||||||||||  Cubicin (daptomycin) / Merck (MSD)
Enrollment change:  Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation (clinicaltrials.gov) -  Dec 27, 2012
P=N/A, N=0, Withdrawn,  Sponsor: Federico II University
Recruiting --> Withdrawn N=100 --> 0



	Diseases Companies Products Productz Mechanisms of Action Sites